Format

Send to

Choose Destination
Diabetes Obes Metab. 2017 Jan;19(1):33-39. doi: 10.1111/dom.12759. Epub 2016 Sep 8.

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.

Author information

1
Eli Lilly and Company, Indianapolis, Indiana.
2
Lilly-NUS Centre for Clinical Pharmacology, Singapore, Singapore.
3
Profil, Neuss, Germany.

Abstract

AIMS:

LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes, but with identical amino acid sequences. This study compared the duration of action of LY IGlar and IGlar in subjects with type 1 diabetes mellitus (T1DM).

MATERIALS AND METHODS:

This was a randomized, double-blind, single-dose, two-period, crossover study. Twenty subjects underwent 42-hour euglycaemic clamps after a single subcutaneous 0.3-U/kg dose of LY IGlar or IGlar. In this study, the duration of action was defined as the time required for blood glucose levels to rise consistently above a predefined cut-off of 8.3 mmol/L (150 mg/dL) from a state of euglycaemia. Blood samples were collected to measure blood glucose for pharmacodynamic (PD) evaluations.

RESULTS:

End of action was reached within 42 hours in 26 of 40 clamps (13 LY IGlar and 13 IGlar). The median duration of action for all subjects was 37.1 and 40.0 hours, and the mean duration of action (calculated using only patients who reached end of action) was 23.8 and 25.5 hours for LY IGlar and IGlar, respectively. The duration of action was demonstrated to be similar between the treatments using time-to-event analysis (log-rank test of equality p = .859). Following administration of LY IGlar and IGlar, the PD parameters of maximum glucose infusion rate (R max ) and total glucose infusion during the clamp (G tot ) were comparable.

CONCLUSION:

LY IGlar and IGlar had similar duration of action and comparable PD parameters in subjects with T1DM.

KEYWORDS:

basal insulin; biosimilar insulin; clinical trial; pharmacodynamics; phase I-II study; type 1 diabetes

PMID:
27484286
PMCID:
PMC5215447
DOI:
10.1111/dom.12759
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center